Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers-Reference-Cited by-同舟云学术

Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers

Published:2023-04-14 Issue:8 Volume:66 Page:5753-5773
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Qiu Qianqian¹,Chi Fanglian¹,Zhou Daoguang¹,Xie Zhancheng¹,Liu Yunxiao¹,Wu Hanyu¹,Yin Ziyu¹,Shi Wei¹,Qian Hai¹²^ORCID

Affiliation:

1. Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P.R. China

2. Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P.R. China

Funder

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00036

Reference23 articles.

1. Histone Deacetylase Inhibitors as Anticancer Drugs

2. HDAC inhibitor-based therapies: Can we interpret the code?

3. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials

4. Histone Deacetylase Inhibitors: From Bench to Clinic

5. Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer;ACS Medicinal Chemistry Letters;2024-08-22

2. Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer;Bioorganic & Medicinal Chemistry;2024-08

3. Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer;Journal of Experimental & Clinical Cancer Research;2024-07-11

4. Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer;European Journal of Medicinal Chemistry;2024-04

5. Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy;Frontiers in Pharmacology;2024-01-03